Study on Dynamic Changes of Human Papillomavirus 16 E5 Gene in the Occurrence of Cervical Cancer

LI Mao-yuan, JIAN Jie, LIANG Kai-ru, YU Jing-rui, LI Ming, TANG Feng-zhu, LI Wan-yi

Abstract

To explore the dynamic changes of human papillomavirus (HPV) type 16 E5 gene in the development of cervical cancer and the significance of E5 mRNA in early screening of cervical cancer.  Methods  Paraffin specimens of cervical lesions were collected from 49 cases (HPV positive) during September 2015 to December 2017 According to the standard of FIGO, all cervical lesions were diagnosed as: 13 cases of cervicitis, cervical intraepithelial neoplasia disorders (CIN) Ⅰ in 5 cases, CIN Ⅱ in 18 cases, CIN Ⅲ in 5 cases, 8 cases of cervical cancer. Real-time fluorescence quantitative PCR was used to detect the integrity of E5 gene and the mRNA expression levels of E5, E6 and E 7in cervical tissues.  Results  All the 49 cases showed positive HPV16 infection. E5 genetic integrity in CINⅠwas higher than that in cervical inflammation, CIN Ⅱand cervical cancer (P < 0.05), which was also higher than that in CIN Ⅲ, but without statistically significance (P>0.05). The mRNA levels of E5, E6, E7 were the highest in CIN Ⅲ. Compared with E6 and E7, E5 presented superior expression in all types of cervical lesions (P < 0.05), while E 6and E7 mRNA expressions only increased in CIN Ⅲ and cervical cancer.  Conclusion  In the patients with HPV16 infection, the integrity of E5 gene in cervical tissues may be related to the occurrence and development of cervical diseases. E5 gene is expected to be the target gene for early screening of cervical cancer.

 

Keywords: Human papillomavirus 16, Cervical lesions, E5 gene, Real-time fluorescence quantitative PCR

 

Full Text:

PDF


References


FREDDIE В, JACQUES F, ISABELLE S, et al. Global cancer statistica 2018; GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin,2018,68(6) ;394-424.

ZUR HAUSEN H. Papillomaviruses in human cancer. Appl Pathol, 1987,5(1): 19-24.

TOMMASINO M. The human papillomavirus family and its role in carainogenesis. Semin Cancer Biol, 2014, 26; 13-21 [2018-10-08]. https;//doi. org/10. 1016/j. semcancer. 2013. 11.002.

LEESJ, YANG A, WU T C, et al. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. J Gynecol Oncol. 2016,27( 5 ): e51 [2018-10-08]. https://doi.org/10.3802/ jgo. 2016. 27. e51.

MURDIYARSO L S, KARTAWINATA M, JENIE I, et al. Single and multiple high-risk and low-risk Human Papillomavirus association with cervical lesions of 11, 224 women in Jalarta. Cancer Causes Control, 2016, 27 ( 11 ): 1371-1379.

IARC Working Group on the Evaluation of Carcinogenic Risks to Human. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum,2007,90:1-636.

SMALL W. Jr. BACON M A, BAJAJ A, et al. Cervical cancer;a global health crisis. Cancer. 2017, 123 ( 13 ); 2404- 2412.

BAKER С C, PHELPS W C, LINDGREN V, et al. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol, 1987,61(4):962-971.

BAGARAZZI M L, YAN J, MORROW M P. et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med, 2012, 4 ( 155 ): 155ral38 [ 2018-10-08 ]. https;//stm. sciencemag. org/content/4/155/155ral38. long. doi: 10.1126/scitranslmed. 3004414.

PAOLINI F, CURZIO G, CORDEIRO M N, et al. HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy. Hum Vaccin Immunother, 2017,13(2):291-297.


Refbacks

  • There are currently no refbacks.